Marie Balsat1, Madeleine Etienne2, Mohamed Elhamri2, Sandrine Hayette3, Gilles Salles1, Xavier Thomas1. 1. Department of Clinical Hematology, Hospices Civils de Lyon, Lyon-Sud Hospital, Pierre Bénite, France. 2. Department of Hematology, Clinical Research Unit, Hospices Civils de Lyon, Lyon-Sud Hospital, Pierre Bénite, France. 3. Laboratory of Molecular Biology, Hospices Civils de Lyon, Lyon-Sud Hospital, Pierre Bénite, France.
Abstract
BACKGROUND: Management of pregnant patients with BCR-ABL-positive leukemia is challenging. Managing a patient who has been diagnosed while pregnant requires a different approach as compared to a patient who plans to become pregnant while on the treatment with tyrosine kinase inhibitor (TKI). Interferon (IFN)-alpha is a useful option in both situations due to teratogenic potential of TKIs. METHODS: We presented a series of 12 successful pregnancies in 11 women with BCR-ABL-positive leukemia, whose leukemia was managed with IFN-alpha throughout their pregnancy. RESULTS: All children have normal growth and development. All patients remained at least in hematological response and could start or resume TKI after delivery or breastfeeding. CONCLUSION: Because of the increased risk of teratogenicity and spontaneous abortion in female patient with pregnancy, when receiving TKI, IFN-alpha can be considered a safe drug to be administered throughout pregnancy and could represent the drug of choice in this situation during the era of TKI therapy.
BACKGROUND: Management of pregnant patients with BCR-ABL-positive leukemia is challenging. Managing a patient who has been diagnosed while pregnant requires a different approach as compared to a patient who plans to become pregnant while on the treatment with tyrosine kinase inhibitor (TKI). Interferon (IFN)-alpha is a useful option in both situations due to teratogenic potential of TKIs. METHODS: We presented a series of 12 successful pregnancies in 11 women with BCR-ABL-positive leukemia, whose leukemia was managed with IFN-alpha throughout their pregnancy. RESULTS: All children have normal growth and development. All patients remained at least in hematological response and could start or resume TKI after delivery or breastfeeding. CONCLUSION: Because of the increased risk of teratogenicity and spontaneous abortion in female patient with pregnancy, when receiving TKI, IFN-alpha can be considered a safe drug to be administered throughout pregnancy and could represent the drug of choice in this situation during the era of TKI therapy.
Authors: Guilherme Antonio de Souza Silva; Suéllen Pedrosa da Silva; Marcos Aurélio Santos da Costa; Abdênego Rodrigues da Silva; Robson Raion de Vasconcelos Alves; Fernanda das Chagas Ângelo Mendes Tenório; Alanne Rayssa da Silva Melo; Antonio Carlos de Freitas; Cristiane Moutinho Lagos de Melo Journal: J Gynecol Obstet Hum Reprod Date: 2020-06-26
Authors: Ernesto Antonio Figueiró-Filho; Richard P Horgan; Nidal Muhanna; Jacqueline Parrish; Jonathan C Irish; Cynthia V Maxwell Journal: AJP Rep Date: 2019-01-29